The fact that treatment with cytotoxic agents can induce myelodysplasia (MDS) and acute myeloid leukaemia (AML) in patients suffering from cancer and from other diseases has now been thoroughly documented (Kyle et al., 1970; Reimer et al., 1977; Casciato & Scott, 1979; Berk et al., 1981; Coltman, 1982; Green et al., 1982; Pedersen-Bjergaard & Larsen, 1982; Boice et al., 1983; Boivin & Hutchinson, 1984; Lakhani, 1984) . However, quantitative relationships with the dose and duration of treatment for different agents, and the relative oncogenic potential of different drugs have yet to be clearly elucidated. It is also not known whether susceptibility to this outcome is influenced by the condition being treated. As a class, the alkylating agents have been shown to be particularly capable of inducing MDS and AML, and there are many reports of both cyclophosphamide and melphalan inducing MDS and AML in patients with mylelomatosis and other neoplasms (Kyle et al., 1970; Gonzalez et al., 1977; Bergsagel et al., 1979; Casciato & Scott, 1979; Buckman et al., 1982; Coltman, 1982) . A quantitative comparison of the relative potency in doing so of these two drugs is more difficult to obtain. In the first two trials in myelomatosis of the Medical Research Council's Working Party on Leukaemia in Adults patients were allocated at random to be treated by either cyclophosphamide or melphalan, and the long-term follow-up of these patients offers a rare opportunity to assess the relative oncogenic potential of these two drugs.
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Patients and methods
The population at risk comprised all patients randomised in the first two Medical Research Council trials (MRC, 1973; MRC, 1980a In examining the blood and bone-marrow films, the diagnosis of MDS or AML was made according to the proposals of the French-American-British (FAB) cooperative group (Bennett et al., 1982) . In brief, the diagnosis of leukaemia was made only when blast cells accounted for >30% of the nucleated cells in the bone marrow; when the blast-cell count was 5-20% the condition was diagnosed as refractory anaemia with excess of blasts (RAEB) and when it was .20% but <30% as RAEB in transformation (RAEBt). Myeloma cells were omitted in performing the differential counts. The slides from one patient from the first MRC trial had been examined for our first follow-up study (Buckman et al., 1982) and the diagnosis was of MDS and AML, but the slides were not available for review on this occasion. Slides were available for review for 3 of the remaining five patients from the first trial and this led to revision of the diagnosis from MDS and AML to MDS alone in all three. The slides from all patients in the second trial were reviewed.
Statistical methods
The main method of analysis was the proportional hazards model with time-varying covariates (Cox, 1972 (1987), 55, 523-529 kl--" The Macmillan Press Ltd., 1987 that of all other patients who has survived for at least as long. Note The risk associated with cyclophosphamide was examined by looking at the model )(t,;, yt) = 0(t)(zt + byt) (A.4) where Yt measured cumulative duration of treatment with cyclophosphamide. The estimated value for 6 was negative, although non-significantly so, implying the cyclophosphamide treatment was not predictive of the risk of MDS or AML in these data.
These models can also be used to predict the prevalence of MDS or AML at given follow-up times. Prediction based on relative risk models will consist of jumps at the observed event times, and in order to get a smoother prediction curve, an absolute risk model was also used. In effect this assumes the baseline hazard rate to be constant and allows one to compute an absolute risk for a given duration of treatment. The model takes the specific form A(t, z,) = az,.
(A.5) The Wilcoxon rank-sum test is also used (Armitage, 1971) and a generalization of it to treat multiple strata was used to give a nonparametric ranking test for association between MDS or AML and length of time on chemotherapy (Cuzick, 1985) . All significant levels are based on 2-sided tests.
Results
Twelve patients were found to have developed MDS (9 cases) or MDS and AML (3 cases). Of the nine MDS cases, six were instances of RAEB and three of RAEB-t. There were no cases of refractory anaemia with or without ring sideroblasts or chronic myelomonocytic leukaemia. In this report all twelve patients who developed MDS or AML (who will be referred to as 'cases' below) are considered as a single group. Details are shown in Table I In Figure 1 the crude (unadjusted for covariates) actuarial cumulative incidence of MDS or AML is plotted. The incidence is 3% after five years of follow-up, 10% after eight years, and 20% after ten years although this last figure has a large standard error (±6%). There figures are less than those reported by Bergsagel et al., 1979. None of the presentation features of the patients who developed MDS or AML differed significantly from those of the other three-year survivors. In the first three years of follow-up cases received cytotoxic treatment for an average of 34.0 months which did not differ significantly from the 31.6 months on treatment for controls (see Table II ). The risk associated with cyclophosphamide treated was examined by looking at the model (A.4). No risk could be associated with treatment using this drug. In a similar way melphalan treatment was broken down into two variablesmonths of daily treatment and months of intermittent treatment. Both items had very similar coefficients (that for daily treatment being 90% of the value for intermittent administration). We concluded that these two modes of administration were similar in their ability to induce MDS or AML, and that they could be combined when assessing duration of treatment.
We have pursued the question of duration of exposure further by examining the predictive value of the amount of treatment given in the period 3 or 5 years before the development of MDS or AML (and a similar interval in controls). These results are summarised in Table III and are plotted for the 3-year period in Figure 3 . In general the relationship to melphalan was strengthened in each case. The strongest relationship was found by looking at the amount of melphalan in the three years before developing MDS or AML (LRX2=16.72, 2P= 0.0001) although the results were almost as strong when a 5-year window was used (LRX2 = 12.97, 2P=0.0003). When assessed by the nonparametric ranking technique (Cuzick, 1985) the duration of melphalan treatment in the past three years was also highly significant (2P=0.005). After allowing for the duration of melphalan treatment in the past three years, no predictive value could be found for previous treatment with any cytotoxic agent or previous melphalan treatment either considered alone or as an interaction with melphalan :.a. treatment in the most recent three years (Data not shown). Also there was still no relationship with duration of cyclophosphamide treatment when therapy in the previous 3-or 5-year interval was analyzed.
An attempt has been made to predict the incidence of MDS or AML as a function of the duration of melphalan treatment. With so few data as these, the predictions must be taken more as working approximations rather than absolute estimates. The models used are simplified idealizations. For example, the observation that duration of melphalan treatment in the last three years gave a more significant effect than total duration of treatment, should not be taken to imply that the risk of MDS or AML is zero after three years off treatment, but only that it is much reduced.
While not being quite as significant, the amount of treatment in the past 5 years is likely to be a better model for prediction. Accordingly, we have used the absolute risk model with a 5-year treatment window for the predictions in Figure 4 . The predicted prevalence of MDS or AML in the absence of other causes of death are plotted as a function of follow-up time for the following model treatment schedules: 1, 2, 3, or 5 years of treatment and then stopping, indefinite treatment, and treatment in alternate years (i.e. 1, 3, 5, etc). At five years follow-up the predicted prevalence of MDS or AML was 2.7%, 4.8%, 6.2% and 7.4% for patients treated for 1, 2, 3, and 5 years respectively. At 10 years the estimates were 3.0%, 6.0%, 8.8%, 14.2% respectively and patients treated continuously for ten years had a 20.6% prevalence. The prevalence on the alternating schedule was 4.5% at 5 years and 11.6% at 10 years. Comparable results were obtained with the discrete proportional hazards model (eqn. A.2), but the curves are less easily interpreted step functions. As a rough guide, it would appear that the 10-year risk of MDS or AML is about 3% for every year of melphalan treatment.
Discussion
Considerable evidence has accumulated to suggest that cytotoxic agents in general, and the biological alkylating agents in particular, induce haemopoietic neoplasia in patients suffering from myelomatosis. However, alkylating Detailed studies on large numbers of patients will be needed to resolve these issues. If melphalan were the only drug or the best drug capable of controlling myelomatosis, it would be desirable to reduce the period of administration to the shortest consistent with optimal control. In the third MRC trial (MRC, 1980b) it was indeed found that, for good risk patients, there was no therapeutic advantage in continuing treatment beyond one year. The lack of advantage in continued treatment has been confirmed in the fourth MRC trial (MRC, 1985) in which patients randomised to receive one further year of chemotherapy after having achieved a stable 'plateau' phase (defined as no downward trend in paraprotein levels for six months) have fared no better than those who stopped cytotoxic treatment at plateau. In the first trial, the protocol called for melphalan to be administered continuously at low daily dosage, whilst in the second it was administered at higher daily dosage for 7 consecutive days every month. There was no significant difference in oncogenicity between the two schedules, though the numbers are not large enough to draw a firm conclusion on this.
Acute myeloid leukaemia was the first neoplasm to be associated with the long-term administration of alkylating agents and much effort has gone into the estimation of the frequency of its occurrence. However, in the great majority of cases of drug-induced leukaemia, the terminal overt acute leukaemia develops from a bone marrow already abnormal as a result of drug-induced neoplasia. This takes the form of grossly disturbed and ineffective haemopoiesis involving all three haemopoietic cell lineages, and is probably a clonal proliferation of a pluripotential stem cell because clonal chromosomal abnormalities are found in almost every case (Nowell et al., 1978; Rowley, 1983; Pedersen-Bjergaard et al., 1984) . The ineffective haemopoiesis results in cytopenias affecting one, two or all three cell lines and the resulting clinical and haematological states are now known as the myelodysplastic syndromes (MDS). Their rate of progression is variable and the patients may survive for months or years. A majority of the patients die as a result of the cytopenias, but most of the remainder die from acute myeloid leukaemia which develops as a result of the malignant transformation of the already neoplastic myelodysplastic stem cell. Rarely, the terminal leukaemia is of lymphoid origin suggesting that the dysplastic stem cell is a pre-lymphoid pre-myeloid cell (Pereira et al., 1985) . MDS is occasionally found in the bone marrow in myelomatosis before any treatment has been administered (Mufti et al., 1983) . Indeed, the increasing incidence of leukeamia with the duration of myelomatosis has been attributed to a special susceptibility of myelomatosis patients to the development of acute leukaemia (Bergsagel, 1982) . If this were so, it would be difficult to explain the clear relationship we have found with melphalan treatment.
Attempts to estimate the oncogenic potential of cytotoxic drugs therefore require the recording of cases of MDS as well as those of overt acute myeloid leukaemia. It is true that, in the past, at least some cases of MDS would have been diagnosed as leukaemia (as in four of the cases included in our report on the first trial) but the proportion is unknown; it is likely, too, that some who died from MDS without having progressed to overt acute myeloid leukaemia would not have been recorded. Thus the true incidence of drug-induced haemopoietic ncplasia may have been underestimated. In our own series we have followed the recommendation of the FAB cooperative group which proposed semiquantitative guidelines for distinguishing the MDS from overt acute myeloid leukaemia. Of the 12 cases only one was found to have overt leukaemia. In 9 of the others only MDS could be documented (six with refractory anaemia with excess of blasts (RAEB), and three of RAEBin-transformation), while in two cases slides were not available to review the diagnosis. All twelve cases are considered as a single group in the analysis.
Drug-induced haemopoietic neoplasia is an excellent model for examining the biology of chemical carcinogenesis. It may also throw light on the transformation of cells by environmental carcinogens, because the primary myelodysplastic syndromes of old age, whose essential features are identical with those of the drug-induced MDS, are increasing in frequency as the age structure of the population is changing. Finally, the study of drug-induced haemopoietic neoplasia may help in the identification of persons particularly susceptible to specific chemical carcinogens of both medical and environmental origin.
